Maintaining the silence: reflections on long-term RNAi

Since the demonstration of RNA interference (RNAi) in mammalian cells, considerable research and financial effort has gone towards implementing RNAi as a viable therapeutic platform. RNAi is, without doubt, the most promising strategy for the treatment of human genetic disorders. Because many of the...

Full description

Saved in:
Bibliographic Details
Published inDrug discovery today Vol. 13; no. 21; pp. 917 - 931
Main Authors Raemdonck, Koen, Vandenbroucke, Roosmarijn E., Demeester, Joseph, Sanders, Niek N., De Smedt, Stefaan C.
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 01.11.2008
Elsevier
Subjects
Animals
Biological and medical sciences
Gene Silencing
General pharmacology
Humans
Kinetics
Medical sciences
Models, Statistical
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
RNA Interference
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - adverse effects
RNA, Small Interfering - therapeutic use
Intracellular transport
RNA interference
Transcription
Drug carrier
Review
Long term
Modeling
Extracellular space
Research and development
Genetic disease
Gene silencing
Perspective
Mathematical model
Gene therapy
Online AccessGet full text

Cover

More Information
Summary:Since the demonstration of RNA interference (RNAi) in mammalian cells, considerable research and financial effort has gone towards implementing RNAi as a viable therapeutic platform. RNAi is, without doubt, the most promising strategy for the treatment of human genetic disorders. Because many of the targets proposed for RNAi therapy require chronic treatment, researchers agree that the emphasis must now be placed on the safe and long-term application of RNAi drugs to reap the benefits at last.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2008.06.008